Skip to main content

Table 1 Clinical and tumor characteristics stratified according to HMG-CoAR protein expression in two independent cohorts

From: Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen

 

Cohort I

Cohort II

 

Low HMG-CoAR (%) (n = 62)

High HMG-CoAR (%) (n = 93)

P value (χ2test)

HMG-CoAR-negative (%) (n = 222)

HMG-CoAR-positive (%) (n = 200)

P value (χ2test)

Age (years)

      

   <median

34 (55)

42 (45)

0.238

36 (16)

36 (18)

0.612

   >median

28 (45)

51 (55)

 

186 (84)

164 (82)

 

Tumor size

      

   0 to 20 mm

21 (35)

57 (63)

0.003

75 (34)

79 (40)

0.196

   >21 mm

39 (65)

33 (37)

 

147 (66)

120 (60)

 

   Missing

5

     

Histological subtype

     

   Ductal

49 (79)

75 (81)

0.250

181 (91)

171 (93)

0.581

   Others

13 (21)

18 (19)

 

17 (9)

13 (7)

 

   Unknown

   

40

  

Nodal status

      

   N0

21 (35)

57 (63)

0.003

70 (32)

42 (21)

0.009

   N1+

39 (65)

33 (37)

 

152 (68)

158 (79)

 

   Unknown

5

     

Nottingham Histological Grade

    

   I

9 (15)

12 (13)

0.535

15 (7)

28 (15)

0.009

   II

38 (60)

56 (60)

 

85 (40)

86 (45)

 

   III

10 (14)

23 (27)

 

115 (53)

79 (40)

 

   Unknown

7

  

14

  

ER status

      

   Negative

   

80 (38)

54 (28)

0.026

   Positive

   

130 (62)

141 (72)

 

   Unknown

   

17

  

PR status

      

   Negative

   

78 (38)

56 (30)

0.098

   Positive

   

130 (62)

133 (70)

 

   Unknown

   

25

  

Ki-67

      

   <10%

   

138 (73)

128 (71)

0.658

   >10%

   

52 (27)

53 (29)

 

   Unknown

   

51

  

Her2 immunohistochemistry

     

   0 to 2+

   

173 (90)

137 (80)

0.008

   3+

   

20 (10)

35 (20)

 

   Unknown

   

57

  
  1. Data in parenthesis are percentages unless otherwise stated. ER, estrogen receptor; HMG-CoAR, 3-hydroxy-3-methylglutharyl-coenzyme A reductase; N0, node-negative; N1+, node-positive; PR, progesterone receptor.